{"created":"2023-05-15T14:46:19.494506+00:00","id":63592,"links":{},"metadata":{"_buckets":{"deposit":"890c2073-b3e6-4bab-bcf8-73f56b1aa695"},"_deposit":{"created_by":1,"id":"63592","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"63592"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00063592","sets":["10:29"]},"author_link":["627623","627622","627617","627620","627616","627614","627621","627619","627615","627618","627613","627624"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2009-10-03","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"抗精神病薬の作用は脳内ドーパミンD2レセプターの遮断作用が主なものであるが、本研究では抗精神病薬がドーパミン作動性神経のシナプス前機能に及ぼす影響について検討した。男性健常者12名を対象に、第２世代抗精神病薬リスペリドン0.5〜2.0 mgの服薬前と服薬後のそれぞれで、[C-11]DOPAおよび[C-11]racloprideを用いたPET検査を行い、線条体における服薬による脳内ドーパミン生成能の変化およびドーパミンD2レセプター占有率を測定した。服薬による脳内ドーパミン生成能変化率とドーパミンD2レセプター占有率との間に明らかな相関はみとめられなかったが、服薬前の脳内ドーパミン生成能と服薬による脳内ドーパミン生成能変化率との間には有意な負の相関がみられ、脳内ドーパミン生成能が服薬により一定値に収束する傾向がみられた。これはリスペリドンに脳内ドーパミン生成能を安定化させる作用があることを示唆するものであり、統合失調症における治療効果発現に関与している可能性がある。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第49回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊藤, 浩"}],"nameIdentifiers":[{"nameIdentifier":"627613","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高野, 晴成"}],"nameIdentifiers":[{"nameIdentifier":"627614","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高橋, 英彦"}],"nameIdentifiers":[{"nameIdentifier":"627615","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"荒川, 亮介"}],"nameIdentifiers":[{"nameIdentifier":"627616","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小高, 文聰"}],"nameIdentifiers":[{"nameIdentifier":"627617","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原, 哲也"}],"nameIdentifiers":[{"nameIdentifier":"627618","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"伊藤 浩","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627619","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高野 晴成","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627620","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高橋 英彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627621","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"荒川 亮介","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627622","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小高 文聰","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627623","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原 哲也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"627624","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"抗精神病薬による脳内ドーパミン生成能変化の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"抗精神病薬による脳内ドーパミン生成能変化の検討"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-10-05"},"publish_date":"2009-10-05","publish_status":"0","recid":"63592","relation_version_is_last":true,"title":["抗精神病薬による脳内ドーパミン生成能変化の検討"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:21:13.334714+00:00"}